An Early Phase 1 interventional study of Placebo and Very Low Dose THC in Psychosis, Cannabis Use and THC, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Yale University · Early Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dronabinol in Psychotic Disorders — none open to participants now, 2 under way, none of them phase 3. Dronabinol · Psychotic Disorders.
Among the 10 studies testing dronabinol in Psychotic Disorders, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 7th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →None of the 10 studies testing dronabinol in Psychotic Disorders is open now. The open studies under Psychotic Disorders, anywhere →
Dronabinol: first FDA approval 1985 (MARINOL). What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 33 across the 10 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 2 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
38 studies in Psychotic Disorders by Yale University: 1 open now, 3 under way, none of them phase 3. Of 34 finished, 10 (29%) have results posted.
Among the 38 studies in Psychotic Disorders by Yale University, this one is the 22nd largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2014, is one of 16 in phase 1, and was the 24th registered.
Yale University’s Psychotic Disorders studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing dronabinol in Psychotic Disorders, from their registry updates:
Among Yale University’s 38 in Psychotic Disorders:
This tab as a report to print or save as PDF → With an account.
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Inclusion Criteria FHP:
Exclusion Criteria FHP:
Inclusion Criteria FHN :
Exclusion Criteria FHN:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
Drug: Placebo · Drug: Very Low Dose THC · Drug: Low Dose THC
Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
Drug: Placebo · Drug: Very Low Dose THC · Drug: Low Dose THC
placebo
Subjects will receive 0.010mg/kg.
Also known as: delta 9-tetrahydrocannabinol
Subjects will receive 0.018 mg/kg over 20 minutes.
Also known as: delta 9-tetrahydrocannabinol
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.
Time frame: -30 min from administration of THC
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.
Time frame: +80 min from administration of THC
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.
Time frame: +150 min of administration of THC
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.
Time frame: +240 min of administration of THC
Clinician Administered Dissociative Symptoms Scale (CADSS)
Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.
Time frame: -30 min, +15 min, +80 min, +150 min, +240 min
Visual Analog Scale (VAS)
Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects.
Time frame: -30 min, +15 min, +80 min, +150 min, +240 min
Hopkins Verbal Learning Test (HVLT)
The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects.
Time frame: +50 min
Psychotomimetic States Inventory (PSI)
The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.
Time frame: -30 min, +240 min
The record gives a start of Jan 2014, a primary completion of Jun 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → Jun 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol